A new phase 2 trial will test JNJ-101556143, also known as HLD-0915, in men with metastatic prostate cancer that has become resistant to androgen-pathway treatment. The study plans to enrol about 100 patients and will evaluate whether the drug can produce objective tumour responses, making this a clear step beyond the earlier dose-finding programme. JNJ-101556143 […]
A new first-in-human phase 1 trial, has been posted for JUR-003 in metastatic prostate cancer. The study plans to enrol up to 210 patients and includes dose-escalation and dose-expansion cohorts in mCRPC, metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease. JUR-003 will be given intravenously, with the initial goals of defining safety, pharmacokinetics and a […]
We already discussed ENV105 (carotuximab) in a previous ProstateWarriors article, when the safety lead-in of its phase 2 trial in metastatic castration-resistant prostate cancer was completed. Since then, the programme has produced its first meaningful efficacy signal, making it worth revisiting. ENV105 targets CD105, a protein that appears to become more active as prostate cancer […]
An inexpensive antifungal drug that has been used for decades is now being tested as a prostate cancer treatment. The phase 2 TerbinaPro trial is evaluating terbinafine in men whose prostate cancer has returned biochemically after previous treatment. Behind this unusual drug-repurposing trial lies an intriguing discovery about how prostate cancer produces cholesterol. The target […]
A next-generation PARP inhibitor called SNV1521 is showing early signs of activity in advanced prostate cancer, while potentially causing less bone-marrow toxicity than existing PARP drugs. SNV1521 is an oral drug designed to selectively inhibit PARP1 while largely sparing PARP2. Current PARP inhibitors such as olaparib inhibit both proteins, and suppression of PARP2 is thought […]
A blood test taken before starting treatment could help identify men with metastatic hormone-sensitive prostate cancer (mHSPC) who are at greater risk of developing treatment resistance early. We have already discussed the importance of ctDNA after treatment in a previous article, but this new study looks at its potential value even before treatment begins. A […]
A new prospective clinical study suggests that radium-223 may change the immune environment of prostate cancer bone metastases in a way that makes subsequent immunotherapy less effective. The study included 28 men with metastatic castration-resistant prostate cancer (mCRPC) and predominantly bone metastases. Patients received radium-223, with six injections planned at four-week intervals. Researchers wanted to […]
A newly registered phase 1 trial is taking an interesting approach to one of the limitations of T-cell engagers in prostate cancer: rather than simply trying to make them more powerful, it will test whether a second immune signal can make their activity more durable. The trial will evaluate JANX007 together with the new drug […]
A new antibody-drug conjugate has received clearance to enter clinical trials in China with a double strategy for prostate cancer: instead of targeting PSMA or STEAP1, ICP-B381 targets both. The experimental bispecific ADC combines a humanised antibody recognising PSMA and STEAP1 with a proprietary cytotoxic payload connected through an irreversible linker. Both proteins are strongly […]
Tinengotinib (TT-00420), a multikinase inhibitor with a distinctive target profile, is showing early signals in metastatic castration‑resistant prostate cancer (mCRPC), a setting where options after modern androgen‑receptor pathway inhibitors and taxanes remain limited. Results from a US‑based, multicenter phase 1/2 trial, published in Clinical Cancer Research, reported an objective response rate of 33.3% in a […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy